96 results about "Herpesvirus infection" patented technology

The invention relates to pharmaceutical compositions for topical administration comprising a topically acceptable antiviral substance and an antiinflammatory glucocorticoid in a pharmaceutically acceptable carrier. The pharmaceutical composition can be used in the prophylactic and curative treatment of herpesvirus infections in mammals including man. The invention also relates to the use of a combination of a topically acceptable antiviral substance and an antiinflammatory glucocorticoid for the manufacture of a medicament for said prophylactic and curative treatment.

The present invention relates to a dandelion plant phenolic acid effective component for preventing and curing herpes simplex virus infection and its application in preparation of medicine for preventing and curing ulcerative stomatitis. The invented dandelion plant phenolic acid effective component is obtained by using fresh dandelion plant or dried dandelion plant and making it undergo the processes of alcohol and water extraction, column chromatography and alcohol solvent elution, etc. Said effective component can be made into lozenge, powder preparation, spray, granules and oral solution, etc.

The invention provides a compound of formula I: wherein R1, R2, R3, and R4 have any of the values defined in the specification, or a pharmaceutically acceptable salt thereof, as well as processes and intermediates useful for preparing such compounds or salts, and methods of treating a herpesvirus infection, atherosclerosis or restenosis using such compounds or salts.

The invention relates to pharmaceutical compositions for topical administration comprising a topically acceptable antiviral substance and an antiinflammatory glucocorticoid in a pharmaceutically acceptable carrier. The pharmaceutical composition can be used in the prophylactic and curative treatment of herpesvirus infections in mammals including man. The invention also relates to the use of a combination of a topically acceptable antiviral substance and an antiinflammatory glucocorticoid for the manufacture of a medicament for said prophylactic and curative treatment.

PCT No. PCT / SE96 / 00123 Sec. 371 Date Mar. 8, 1996 Sec. 102(e) Date Mar. 8, 1996 PCT Filed Feb. 2, 1996 PCT Pub. No. WO96 / 24359 PCT Pub. Date Aug. 15, 1996The invention relates to a pharmaceutical composition for topical administration comprising a combination of foscarnet and an antiinflammatory glucocorticoid, in admixture with a carrier based on galactolipids and a polar solvent. The pharmaceutical composition can be used in a prophylactic and / or curative treatment of herpesvirus infections in mammals including man. The invention also relates to the use of said pharmaceutical composition in the manufacture of a medicament for said prophylactic or curative treatment.

The invention discloses an application of polycyclic polyketides in preparation of an anti-HV (herpes virus) drug. It is found that the polyketides can inhibit diseases caused by infection of four HVs including HSV-1 (herpes simplex virus-1), HSV-2 (herpes simplex virus-2), VZV (varicella zoster virus) and CMV (cytomegalo virus). The compounds show equivalent activity but have different acting mechanisms as compared with commercial drugs such as acyclovir and can overcome drug resistance of existing commercial drugs. Therefore, the compounds have good application prospects in treatment of related diseases caused by infection of HVs including HSV-1, HSV-2, VZV and CMV.

The invention provides a compound of formula I: wherein G, R2, R3, and R4 have any of the values defined in the specification, or a pharmaceutically acceptable salt thereof, as well as processes and intermediates useful for preparing such compounds or salts, and methods of preventing or treating a herpesvirus infection using such compounds or salts.

Compositions and methods are provided for the treatment and diagnosis of herpesvirus infections. In accordance with preferred embodiments, oligonucleotides are provided which are specifically hybridizable with RNA or DNA deriving from a gene corresponding to one of the open reading frames UL5, UL8, UL9, UL13, UL29, UL30, UL39, UL40, UL42 AND UL52 of herpes simplex virus type 1. The oligonucleotide comprises nucleotide units sufficient in identity and number to effect said specific hybridization. In other preferred embodiments, the oligonucleotides are specifically hybridizable with a translation initiation site; it is also preferred that they comprise the sequence CAT. Methods of treating animals suspected of being infected with herpesvirus comprising contacting the animal with an oligonucleotide specifically hybridizable with RNA or DNA deriving from one of the foregoing genes of the herpesvirus are disclosed. Methods for treatment of infections caused by herpes simplex virus type 1, herpes simplex virus type 2, cytomegalovirus, human herpes virus 6, Epstein Barr virus or varicella zoster virus are disclosed.

The invention is directed to methods and compositions for treating or preventing reactivation of a latent herpesvirus infection and the associated complications and outcomes. The methods involve administering a composition comprising glutamine, or a derivative, conjugate, or analog thereof.

The invention discloses novel applications of a histone deacetylase inhibitor in treatment of beta subfamily herpesvirus, and more specifically provides applications of a histone deacetylase (HDAC) inhibitor or pharmaceutically acceptable salts in preparing of pharmaceutical compositions used for treating beta subfamily herpesvirus. It is confirmed by experiments that low concentration HDAC inhibitor possesses relatively high inhibition efficiency on beta subfamily herpesvirus infection, and inhibition rate is as high as 99.69 to 99.97%. So that the HDAC inhibitor can be taken as an effective drug used for treating beta subfamily herpesvirus infection in clinical.

The present invention relates to an implantable drug delivery device comprising a polymeric or polymeric containing material in combination with a therapeutic compound effective for the treatment of a member of the herpesvirus family, wherein the therapeutic compound is in an amount that will effectively treat HSV-1, HSV 2 and / or VZV or reduce reactivation, and wherein the implantable drug delivery device is positioned at or near the site of latent infection or at the site of observed clinical symptoms. The therapeutic compound may include any active antiherpes agent including acyclovir, guanosine, valacyclovir or functionally active analogues.

The present invention is directed to a mutated recombinant herpesvirus, e.g., varicella zoster virus (VZV) and simian varicella virus strains or HSV-1 or HSV-2 strains, vaccines containing, and methods for the construction and use thereof to elicit protective immunity in susceptible individuals, wherein the particular herpesvirus is modified to render the virus replication deficient, i.e., the virus substantially or only replicates under defined conditions, by the incorporation of at least one destabilization domain in or fused to a gene essential for herpesvirus replication. The invention particularly relates to the use of the resultant conditionally replication defective herpesviruses, e.g., a mutated VZV strains in vaccine compositions in order to immunize individuals against herpesvirus infection, e.g., in the case of VZV chickenpox and to protect against shingles and zoster, or to prevent the reactivation of VZV or other herpesvirus reactivation and the onset of shingles or another condition relating to the reactivation of another herpesvirus infection, e.g., as a consequence of advanced age, stress, inflammation, drug or other therapy, cancer, or immunodeficiency such as in HIV-AIDS or other diseases resulting in impaired T and / or B cell immunity.

The invention provides a compound of formula (I), wherein R<1>, R<2>, R<3>, and R<4> have any of the values defined in the specification, or a pharmaceutically acceptable salt thereof, as well as processes and intermediates useful for preparing such compounds or salts, and methods of preventing or treating a herpesvirus infection using such compounds or salts.

There is provided a pharmaceutical drug, particularly a novel compound useful for prophylaxis or a therapeutic treatment of various diseases involving infections with viruses of the herpesvirus family, specifically various herpesvirus infections such as varicella (chicken pox) via varicella zoster virus, varicella zoster via recurrent infection with latent varicella zoster virus, herpes labialis and herpes encephalitis via HSV-1 and genital herpes via HSV-2 infection. An N-{2-[(4-substituted phenyl)amino]-2-oxoethyl}tetrahydro-2H-thiopyran-4-carboxamide derivative, of which phenyl group is substituted at position 4 with a specific 5- or 6-membered heteroaryl group, and a salt thereof have an effective anti-virus activity, and the oral administration thereof at a low dose enabled the therapeutic treatment of the above diseases.

New application of 16-carbonyl sulfoacid glycerin glucose ester and a preparation method thereof relate to the new application and the preparation method of a compound. The 16-carbonyl sulfoacid glycerin glucose ester extracted from Caulerpa racemosa can be used for preparing the medicine for treating II type herpesvirus infection, which is in particular suitable for preparing the medicine for treating genital herpes. More particularly, Caulerpa racemosa is used as raw material, from which crude extract is extracted with water or ethanol; the crude extract is sequentially extracted by ethyl acetate and normal butanol; the part extracted with normal butanol is firstly separated by silicagel column and then separated by gel column to obtain the 16-carbonyl sulfoacid glycerin glucose ester. The invention has the advantages that the 16-carbonyl sulfoacid glycerin glucose ester is separated from Caulerpa racemosa for the first time; the compound has excellent activity for in vitro resistance of the II type herpesvirus; the growth characteristics of Caulerpa racemosa have threat towards a plurality of creatures and go against the stability of environment, thus the invention not only can change waste into valuable, but also provide sufficient raw material for industrial production.

The invention discloses application of nucleoside type antiviral medicine to preparation of medicine for treating infarction diseases, relates to the technical field of medicine, and aims at providinga novel direction for researching and developing the medicine for treating the infarction diseases. According to the application of the nucleoside type antiviral medicine to preparation of the medicine for treating the infarction diseases provided by the invention, the nucleoside type antiviral medicine can reduce the serious degree and the frequency of herpes simplex virus infection, and also has the significant activity of relieving infarction complications. Studies prove that in the infarction diseases, blood platelet adhesion, activation and aggregation achieve the key regulating effects;the nucleoside type antiviral medicine, such as famciclovir can inhibit the blood platelet aggregation, inhibit the GPIIb / IIIa activation, inhibit P-selectin expression and / or inhibit arteriovenous thrombus and cerebral infarction formation; meanwhile, a blood coagulation system is not influenced; and a novel idea is provided for the research and development of medicine for treating the infarction diseases.

The present invention provides an isolated peptide having an amino acid residue sequence that comprises at least one human cytomegalovirus glycoprotein B (HCMV-gB) sequence segment, each HCMV-gB sequence segment consisting of at least 8 and not more than 60 consecutive amino acid residues from residues 146 to 315, residues 476 to 494 of SEQ ID NO: 1, or from a sequence variant of residues 146 to 315 or 476 to 494 of SEQ ID NO: 1 that has at least 70% sequence identity thereto. The peptides of the invention are useful for treating, preventing, or inhibiting a herpesvirus (e.g., Herpes Simplex Virus-1, Human Cytomegalovirus, and the like) infection in a subject.

The invention relates to a method for using alcaine 13-hexyl berberine and relative alcaine 13-hexyl palmatine to prepare the drug that treats herpesvirus infection on skin mucosa. And said two compounds have strong functions to resist HSV, I, II herpesvirus. And their restrain density (IC50) of external resist HSV-1 type and HSV-2 type is 0.78-1.56 mug / ml. And the 0.5% 13-hexyl berberine or alcaine 13-hexyl palmatine, or 1% emulsion can treat bleb, stronger than 3% assili lovou.

The invention discloses application of raltitrexed or pharmaceutically-acceptable raltitrexed salt to preparation of drugs for treating or preventing herpesvirus infection. Raltitrexed totally without toxin concentration is selected and used for performing an anti-herpesvirus test, a result shows that the compound has remarkable anti-herpesvirus activity and is in dose-dependent correlation, and raltitrexed inhibits virus copying to display the anti-herpesvirus effect. Detection on different subtypes of herpesviruses displays that raltitrexed has wide anti-herpesvirus activity, the selection index is high, raltitrexed can be developed into drugs for treating herpesvirus infection, and wide application prospects are achieved.

The invention relates to a medicinal composition containing C21-C28 fatty alcohols and non-steroidal anti-inflammatory medicaments, which is applicable to the treatment of herpesvirus infection, particularly the recurrent simplex herpesvirus infection of skin or mucous membranes.

The invention provides a compound of formula I: wherein R1, R2, R3, and R4 have any of the values defined in the specification, or a pharmaceutically acceptable salt thereof, as well as processes and intermediates useful for preparing such compounds or salts, and methods of preventing or treating a herpesvirus infection using such compounds or salts.

Methods and compositions are provided for inhibiting or treating a herpesvirus infection in a subject using inhibitors of mammalian Akt.

Disclosed are: an inhibitor of herpesvirus infection; a method for the inhibition of herpesvirus infection; and a typical utilization method thereof. The inhibitor of herpesvirus infection comprises an active ingredient which can bind to glycoprotein B or a receptor for glycoprotein B and can inhibit the interaction between glycoprotein B and a receptor for glycoprotein B.

A Xiduofuwei injection in the form of freeze-dried powder for treating AIDS, cytomegalovirus infection of retina, hepes, simplex virus infection, variola virus infection, etc is prepared from Xiduofuwei, and excipient through proportional dissolving, regulating pH value, filter, quickly freezing, heatingand sublimation drying.

Methods are provided for treating or preventing infections by obligate intracellular prokaryotes, including mycoplasma, rickettsia and chlamydia, and DNA viruses, including herpes viruses, papillomaviruses, adenoviruses and hepatitis B virus. The methods involve the administration of 3:1 complexes of 3-hydroxy-4-pyrones with gallium, e.g., gallium maltolate. Therapies incorporating gallium maltolate in combination with agents used against obligate intracellular prokaryote and DNA virus pathogens are also provided, as are multi-combination therapies designed to treat co-infection by an obligate intracellular prokaryote or DNA virus in an immunocompromised individual. These multi-combination therapies rely on the ability of gallium maltolate to complement antiviral medication regimes against both HIV and other pathogens such as herpesvirus infections, including Kaposi sarcoma, CMV retinitis and blindness, and lymphomas, in patients immunocompromised by HIV infection.

This invention provides methods of screening for compounds that inhibit herpesviral transcription and replication. The methods comprise screening test compounds for ability to enhance the activity of homeodomain transcription factor PDX1 in repressing transcription of herpesviral genes (e.g., the IE gene of cytomegalovirus). Transcriptional repression by PDX1 can be monitored using an expression vector comprising a reporter gene operably linked to a PDX1-binding, upstream transcription regulatory sequence of the herpesvirus. The invention further provides methods and pharmaceutical compositions for stimulating PDX1-mediated transcriptional repression in a subject and for treating diseases and conditions associated with herpesviral infection.

Methods and uses for the treatment of herpesvirus infection based on the inhibition of the interaction between herpesvirus UL24 and non-muscle myosin type IIa (NM2a) are described.

The invention relates to a novel amide derivative which is an N-({[4-(substituted thiazol-4-yl)phenyl]carbamoyl}methyl)amide derivative having a characteristic in that an aryl or heteroaryl group as an aromatic ring group is directly substituted on the N atom of amido group. Since said amide derivative has excellent anti-herpesvirus action, it is useful as medicaments and antiviral agents, particularly as preventive or therapeutic agents for various diseases accompanied by Herpesviridae virus infections, illustratively, varicella (chickenpox) accompanied by varicella zoster virus infection, shingles accompanied by the recurrent infection of latent varicella zoster virus, labial herpes and herpes encephalitis accompanied by HSV-1 infection, genital herpes accompanied by HSV-2 and the like various herpesvirus infections.